Minnesota Journal of Law, Science & Technology
Volume 13

Issue 2

Article 11

2012

The Tension Between Policy and Practice in Returning Research
Results and Incidental Findings in Genomic Biobank Research
Sharon F. Terry

Follow this and additional works at: https://scholarship.law.umn.edu/mjlst

Recommended Citation
Sharon F. Terry, The Tension Between Policy and Practice in Returning Research Results and Incidental
Findings in Genomic Biobank Research, 13 MINN. J.L. SCI. & TECH. 691 (2012).
Available at: https://scholarship.law.umn.edu/mjlst/vol13/iss2/11

The Minnesota Journal of Law, Science & Technology is published by the
University of Minnesota Libraries Publishing.

009 TERRY_PROOF -SK.DOCX (DO NOT DELETE)

7/5/2012 1:21 PM

The Tension Between Policy and Practice
in Returning Research Results and
Incidental Findings in Genomic Biobank
Research
Sharon F. Terry*
I. Introduction ........................................................................... 693
A. Current Policies.......................................................... 694
i. To Return or Not to Return................................ 695
ii. More Recent Policy Recommendations .............. 696
iii. International Issues ........................................... 698
B. Current Practices ....................................................... 699
C. Emergence of Participant-centric Perspectives ........ 700
D. Return of RRs and IFs in Genomics Biobanks:
Something Different than Non-Genomic
Studies? .................................................................... 702
E. The Relativity of Time and Context .......................... 703
II. Tension for Whom? .............................................................. 707
A. Participants ................................................................ 707
i. Expectations ....................................................... 707
ii. Literacy ............................................................... 709
iii. Usefulness........................................................... 709
iv. Support ............................................................... 711
v. Fears ................................................................... 712
1. Discrimination .............................................. 712

© 2012 Sharon F. Terry
* MA, President and CEO, Genetic Alliance. I would like to thank the
individuals who participated in the project for their thoughtful rumination on
RR and IF. I would also like to thank the Genetic Alliance Council and Staff
for discussing various parts of this paper with me. Finally, I am grateful for
my husband Patrick: he remains my most vigorous and resonant sounding
board. Preparation of this article was supported by the National Institutes of
Health (NIH), National Human Genome Research Institute (NHGRI) grant
#2-R01-HG003178 on “Managing Incidental Findings and Research Results in
Genomic Biobanks & Archives” (Wolf, PI; Kahn, Lawrenz, Van Ness, Co-Is).
The contents of this article are solely the responsibility of the author(s) and do
not necessarily represent the views of NIH or NHGRI.

691

009 TERRY_PROOF -SK.DOCX (DO NOT DELETE)

692

MINN. J. L. SCI. & TECH.

7/5/2012 1:21 PM

[Vol. 13:2

2. Lack of Care.................................................. 713
3. Anxiety Associated with Risk ...................... 713
B. Communities .............................................................. 714
i. How Do IFs and RRs Challenge Community
Identity or Norms? ............................................. 714
ii. Increased Data Sharing and Comparison
Through Technology ........................................... 716
iii. Obligation to Share IFs and RRs that Are
Meaningful for the Community ......................... 716
iv. Vulnerable Communities .................................... 717
1. Power Differential When Information is
Not Uniformly Available to All Parties ....... 717
2. Potential Discrimination If RRs or IFs in
a Group Are Aggregated .............................. 717
C. Researchers ................................................................ 718
i. Balancing Benefit and Risk: How to Assess
and from What Perspective? .............................. 720
ii. Returning Findings Are Time and Resource
Intensive: How to Pay for Such Activities? ....... 721
iii. Misconceptions Are Easy to Come by: How
Can We Address Them to Allay Concerns? ....... 721
iv. Communicating with Participants Can Be
Quite Complicated: How Can We Do This? ....... 722
D. Clinicians.................................................................... 722
i. I Lack the Resources to Educate the
Participant .......................................................... 723
ii. I Have X Minutes Per Visit. How Am I Going
to Find Time to Deal with This? ........................ 723
iii. This Is My Patient, but I Have to Share
Him/Her with a Researcher. How Do I
Navigate This Complex Relationship? .............. 723
E. Institutions ................................................................. 724
F. Society ......................................................................... 727
III. Conclusion........................................................................... 730
A. Potential Solutions for Key Challenges .................... 730
i. Reidentification .................................................. 731
ii. Participant-centricity ......................................... 732
iii. Expense/Cost ...................................................... 733
B. The Movement Toward Open Data Sharing ............. 735

009 TERRY_PROOF -SK.DOCX (DO NOT DELETE)

2012]

7/5/2012 1:21 PM

TENSION BETWEEN POLICY AND PRACTICE

693

I. INTRODUCTION
The tensions between policy and practice in returning research results (RRs) and incidental findings (IFs) in genomic
biobank research are readily apparent and potentially increasing as biobanks are built at a more frenzied pace. As a result,
more policies are proffered and practices are ever more widely
varied. Particularly for the Western mind, tension can have
negative connotations, and in the face of it, one may consider
reducing or eliminating it as a productive goal. However, tension is a force of balance, and allowing for a continuum, rather
than a dichotomous world, is a generative role for tension. As
the tension between policy and practice increases, it will lead to
some novel and necessary solutions. In fact, tension can be a
beacon that highlights the critical issues and even helps determine both policy and practice—a generative dialogue shareholders should be part of—as well as what processes will accelerate the balance.
This paper will consider the current tensions between policy and practice from a number of stakeholders’ perspectives. It
will also consider future tensions that might arise as datasharing in general becomes more of a norm and contributors of
biological samples and clinical data become more proactively
engaged in biomedical research.1
Genomic biobank research means different things to many
people. Further, the widely varying results coming from these
biobank systems may lead to varying tensions.2 There are several ways to approach this discussion, and for the sake of using
the various stakeholders as spokespersons for the tensions, we
will use a fairly simple—somewhat inclusive—model. I will
consider the biobank to be the entire system as defined by the
2012 Wolf Consensus Document. Thus, the term biobank refers
to the system of primary researcher, biobank, and secondary
researcher.3

1. See Sharon F. Terry & Patrick F. Terry, Commentary, Power to the
People: Participant Ownership of Clinical Trial Data, 3 SCI. TRANSLATIONAL
MED. 69cm3, at 2 (2011).
2. See generally Jasper Bovenberg et al., Biobank Research: Reporting
Results to Individual Participants, 16 EUR. J. HEALTH L. 229 (2009) (discussing the results of a study on whether and how any results derived from research with large scale biobanks should be communicated to individual research participants).
3. Susan M. Wolf et al., Special Article, Managing Incidental Findings
and Research Results in Genomic Research Involving Biobanks and Archived
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This does not mean that I will simplify to such an extent as
to ignore each of these dimensions. In fact, a complex matrix is
needed to describe the intersection of various continuums. RRs
and IFs can occur in various contexts from research to clinical
care to public health (Figure 1). There are many roles in a
biobank system and only the three delineated by the 2012 Wolf
Consensus Document would be in a position to return RRs or
IFs. Findings might be applicable to an individual, a family, a
community, or to an aggregate population.4 Finally, specific or
general results can be returned.5

Figure 1. Continuum in which RR and IFs occur.
A. CURRENT POLICIES
I begin with a cursory review of policies and practices.6
There are a relatively large number of polices and guidelines
applicable to the governance of biobanks. In a 2008 review of
policies, Haga reported fourteen international guidelines for
biobanks and forty-four national and regional sets of guidelines.7 Some of these guidelines impact the return of RRs and
Data Sets, 14 GENETICS MED., 361 (2012).
4. See id. at 6–7.
5. See id. at 7−8.
6. For a more complete discussion, see Wolf et al., supra note 3.
7. Susanne B. Haga & Laura M. Beskow, Ethical, Legal, and Social Implications of Biobanks for Genetics Research, 60 ADV GENET 505, 509–11
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some IFs, but not all address them explicitly.8 In fact, the 2012
Wolf Consensus Document, in an extensive study, found that
current biobank policies vary and U.S. biobanks are almost
evenly divided on whether they address the return of IFs and
RRs.9
i.

To Return or Not to Return

Biobank policies range from returning no results at all to
returning some results.10 Vanderbilt University Medical Center’s BioVU is “one of few biobanks” set up to conduct
“non-human subjects research” and “the design explicitly precludes re-contact with any individual.”11 This policy rests on an
Office for Human Research Protections (OHRP) guidance that
stated studies with data or samples not collected for the specific
research in question or not readily identifiable sources will not
be considered human subjects research.12
Two recommendations put forth by a working group convened by the National Heart Lung and Blood Institute are also
relevant as an example of a biobank policy:
Recommendation 1[:] Individual genetic results should be offered to
study participants in a timely manner if they meet all of the following
criteria:
a. The genetic finding has important health implications for the
participant, and the associated risks are established and substantial.
b. The genetic finding is actionable, that is, there are established
therapeutic or preventive interventions or other available actions
that have the potential to change the clinical course of the disease.
c. The test is analytically valid, and the disclosure plan complies
with all applicable laws.
d. During the informed consent process or subsequently, the
study participant has opted to receive his or her individual genetic results.13

(2008).
8. See id. at 508–12.
9. Wolf et al., supra note 3, at 365–66.
10. Id.
11. Jill Pulley et al., Principles of Human Subjects Protections Applied in
an Opt-Out, De-Identified Biobank, 3 CLINICAL TRANSLATIONAL SCI. 42, 48
(2010).
12. Guidance on Research Involving Coded Private Information or Biological Specimens, OFF. HUM. RES. PROTECTIONS (Aug. 10, 2004),
www.hhs.gov/ohrp/archive/humansubjects/guidance/cdebiol04.htm.
13. Richard R. Fabsitz et al., Ethical and Practical Guidelines for Report-
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Recommendation 4[:] Investigators may choose to return individual
genetic results to study participants if the criteria for an obligation to
return results are not satisfied (see Recommendation 1) but all of the
following apply:
a. The investigator has concluded that the potential benefits of
disclosure outweigh the risks from the participant’s perspective.
b. The investigator’s I[nstitutional] R[eview ]B[oard] has approved the disclosure plan.
c. The test is analytically valid and the disclosure plan complies
with all applicable laws.
d. During the informed consent process or subsequently, the
study participant has opted to receive his/her individual genetic
results.14

ii.

More Recent Policy Recommendations

After considering these and many other recommendations,
the recommendation made by the 2012 Wolf Consensus Document states what responsibilities biobanks should shoulder:
(1) clarifying the criteria for evaluating findings (e.g., analytic validity, seriousness of condition, and actionability) and the roster of returnable IFs and [RRs]; (2) analyzing a particular finding in light of
those criteria and that roster to determine if it constitutes a returnable IF or [RR]; (3) re-identifying the individual (or individuals) for potential return; and (4) recontacting the individual (or individuals) to
offer the finding.15

Certainly these recommendations shift the onus for returning results from the primary researcher, previously the most
common focus for this responsibility, to the entire biobank research system. The 2012 Wolf Consensus Document defines the
system as including primary and secondary researchers and
the biobank.16 This suggests that the system should ensure
that necessary IFs and RRs are offered to participants, with the
biobank itself responsible for general oversight. The entire
biobank system must have a procedure for evaluating findings,
along with a list of returnable IFs and [RRs], and be responsible for determining which results are offered to participants.17
Furthermore, the biobank research system must be able to

ing Genetic Research Results to Study Participants: Updated Guidelines from a
National Heart, Lung, and Blood Institute Working Group, 3
CARDIOVASCULAR GENETICS 574, 575 (2010).
14. Id. at 577.
15. Wolf et al., supra note 3, at 371.
16. Id. at 3–4.
17. See id. at 9.
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identify and recontact the donor(s) relevant to the finding.18 IFs
and RRs with unlikely net benefit for donors should not be returned; however, there should be a distinction made between
those results biobank systems must return and those that may
be returned, based on net benefit.19 Donors and potential donors should be involved throughout this process by providing
input on their preferences regarding returning results, while
biobanks learn from outcomes, and share experiences with other biobanks, in order to improve the system.20
Funders and regulators must also share some of the responsibility.21 There should be processes for regulators to ensure that biobanks follow the standards set down for returning
results and to support these biobanks in creating and updating
these standards. The Advanced Notice of Proposed Rule Making on the Common Rule (ANPRM) published by the Office of
Human Research Protections (OHRP) in July 2011 proposes
that inclusion of a sample in a biobank will require explicit
consent.22 This proposed new rule arises from concerns that
many biobanks obtain and archive samples without the participants’ knowledge and may resolve some of the complexities inherent in returning results. If biobanks inform and even engage
participants during this consent process by educating them
about having identifying information stored in a way that enables RR, then many of the tensions dissipate. However, OHRP
may have inadvertently disincentivized biobanks from engaging participants since the ANPRM indicates that research that
doesn’t return results is “excused”: a new category that doesn’t
require the researchers go to an IRB to use the samples.23
OHRP asked many questions related to this issue in their request for comments.24
Funders, be they public or private, must recognize the additional burden created by the necessity of having a system for
returning results and must allocate funding accordingly.25

18. Id. at 9–10.
19. Id. at 13.
20. Id. at 19.
21. See id.
22. Human Subject Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators,
76 Fed. Reg. 44512, 44515 (July 26, 2011).
23. Id. at 44518–19.
24. Id. at 44520–21.
25. See Wolf et al., supra note 3, at 364.
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Funders can also require, through a variety of carrot and stick
mechanisms, return of IFs and RRs. They will not be considered in this paper as distinct stakeholders, but are active players in the system and affect the level of tension in the system.
iii. International Issues
Some authors have recommended that it is critical in a
global age that international policies be considered.26 To some
extent, the international community has led policy development in this regard:
Indeed, the [incidental findings] issue was acknowledged by the international community in the mid-1990s in a statement by the international Human Genome Organization (HUGO), which declared that
“choices to be informed or not with regard to results or incidental
findings should . . . be respected.” In its “International Ethical Guidelines for Biomedical Research Involving Human Subjects,” the Council for International Organizations of Medical Sciences (CIOMS) has
provided that “individual subjects will be informed of any finding that
relates to their particular health status.” CIOMS also states that
“subjects have the right of access to their data on demand, even if
these data lack immediate clinical utility.”27

Zawati et al. argue that Spanish law implies that every
person has the right to be informed of his or her genetic data
and other data of a personal nature that are obtained in the
course of a biomedical research.28 Some of these international
policies are worded more strongly than U.S. policies.29 Many of
these policies have their basis in human rights.30 In general,
U.S. policies present themselves as recommendations to the institutions holding the samples, rather than describing the
rights of the participant.

26. See generally Lynn G. Dressler, Biobanking and Disclosure of Research Results: Addressing the Tension Between Professional Boundaries and
Moral Intuition, in THE ETHICS OF RESEARCH BIOBANKING 85 (Jan Helge
Solbakk et al. eds., 2009) (discussing the emerging ethical imperative from international guidelines to communicate research results to the individual and
questioning how that these duties can be implemented in practice).
27. Wolf et al., supra note 3, at 367 (citations omitted).
28. See Ma’n H. Zawati et al., Incidental Findings in Genomic Research: A
Review of International Norms, 9 GENEDIT 1, 5 (2011) (“The Spanish Law confirms the existence of the participant’s right ‘not to know’ about incidental
findings.”).
29. Wolf et al., supra note 3, at 367.
30. See id. at 7–8.
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B. CURRENT PRACTICES
There is significant variation, both within the United
States and abroad, in the practice of how biobanks handle returning IFs and RRs.31 Some biobanks, for instance, offer no results of any kind to research participants, while others only release aggregate data.32
Even within the subset of biobanks offering some form of
returning IFs and RRs, there is still a wide deviation.33 Certain
biobanks offer only IFs to participants or only provide particular individualized RRs, whereas other biobanks consistently offer all IFs and RRs. The Coriell Personalized Medicine Collaborative, for example, is a multi-institutional study in the United
States that periodically offers both IFs and RRs to research
participants.34 On the other end of the spectrum is the Icelandic Biobank, launched in 1998, which gave full ownership of
health information to the state35 and released no results—
aggregate or individual. Most biobanks fall somewhere in the
middle, like the UK Biobank, which offers IFs found during initial testing and grants access to the aggregate results, but it
provides no other IFs or RRs.36
Thus, policy and practice are tightly coupled in a few instances, but for the most part policies regarding return of RRs
or IFs have not yet been formulated and practice varies a great
deal based on the individual researchers involved, the culture
of the institution and the region, and the level of involvement of
the participants.
A project called the Electronic Medical Records and Genomics Network (eMERGE) is potentially a good place to explore the tensions between policy and practice. This is a compilation of five major medical center sites, a data coordinating
center, and National Institutes of Health, using a broad range

31. Id.
32. Id at 5.
33. See, e.g., id. at 5–6 (“Among those biobanks that do address [the issue
of returning IFs and RRs], some return no findings at all, some return nongenetic IFs (such as abnormal blood pressure) discovered at enrollment, some
return a subset of non-genetic or genetic IFs, and some return a subset of nongenetic or genetic [RRs].”).
34. Catharine B. Stack et al., Genetic Risk Estimation in the Coriell Personalized Medicine Collaborative, 13 GENETICS MED. 131, 131 (2011).
35. David E. Winickoff, Partnership in U.K. Biobank: A Third Way for Genomic Property?, 35 J.L., MED. & ETHICS 440, 441 (2007).
36. Haga & Beskow, supra note 7, at 533.
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of community engagement—through surveys and focus
groups—to assess a priori values and concerns.37 In addition,
some biobanks are engaging in deliberative democracy within
the various communities and are also studying population attitudes toward biobanks.38 These sites are involving communities
in design and oversight and allowing these sites to explore participants’ attitudes about policies and practice.39
C. EMERGENCE OF PARTICIPANT-CENTRIC PERSPECTIVES
In the midst of these considerations of returning IFs and
RRs, nonmedical data sharing—with return of results—has become more commonplace. In many areas in life, it is now easy
to access and share data. Feedback is expected and ubiquitous.
Consumers experience this in Netflix recommendations, iTunes
Genius, and Facebook friends’ likes and dislikes. Individuals
share information and experiences in web applications such as
Amazon, Angie’s List, MapMyRide, FitBit, Daily Burn, and Nike and expect results back—how do I stack up against others
and what do I need to change in my shopping, eating, or
workout routine? Models are also emerging in clinical data
sharing with various kinds of feedback and results shared.
23andMe gives individuals their genome sequence and some
research results back.40 Individuals can receive dozens of research results via a password-protected web platform.41 Some
argue that the “23andMe model promotes the idea that curiosity about one’s genome on the one hand, and participation in research on the other, are not only compatible but complementary aspects of being an entrepreneurial subject of
contemporary health and medicine framed by the technologies

37. See Catherine A McCarty et al., The eMERGE Network: A Consortium
of Biorepositories Linked to Electronic Medical Records Data for Conducting
Genomic Studies, 4 BMC MED. GENOMICS 13 (2011) (discussing the general set
up and efficacy of the eMERGE Network).
38. See, e.g., Catherine A. McCarty et al., Community Consultation and
Communication for a Population-Based DNA Biobank: The Marshfield Clinic
Personalized Medicine Research Project, 146A AM. J. MED. GENETICS 3026,
3027–28 (2009).
39. Id.
40. Thomas Goetz, 23AndMe Will Decode Your DNA for $1,000. Welcome
WIRED.COM
(Nov.
17,
2007),
to
the
Age
of
Genomics,
http://www.wired.com/medtech/genetics/magazine/15-12/ff_genomics.
41. Id.
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of web 2.0.”42 The return of these results is not based on clinical
practice guidelines, instead the ‘results’ are based on correlations being established using common evidentiary standards,
for example through genome-wide association studies that have
led to associations with specific conditions.43
In another participatory web service, PatientsLikeMe collects information about individuals, at their own initiative, on
hundreds of aspects of their lives.44 This data, in an aggregated
form, has proven useful to the research enterprise.
PatientsLikeMe and 23andMe have shown through research
conducted in their communities that participatory web services
hold enough power to replicate traditional studies.45
An individual seeking associations relevant to his or her
genome can use an add-on for the Firefox browser called
SNPTips, created by 5 AM | Solutions.46 A person can associate
their 23andMe genome sequence data with SNPTips and
webpages that include single-nucleotide polymorphisms
(SNPs), from news articles to scientific papers, and reveal relevant SNPs.47 This is certainly the tip of the iceberg in ‘network
effect’ tools—tools that will augment the newly emerging data
collections. In another example, Private Access gives individu-

42. Richard Tutton & Barbara Prainsack, Enterprising or Altruistic
Selves? Making Up Research Subjects in Genetics Research, 33 SOC. HEALTH &
ILLNESS 1081, 1081 (2011).
43. See, e.g., Chuong B. Do et al., Web-Based Genome-Wide Association
Study Identifies Two Novel Loci and Substantial Genetic Component for Parkinson’s Disease, 7 PLOS GENETICS, no. 6, 2011, at 1, 2,
http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1002141;
Joyce Y. Tung et al., Efficient Replication of Over 180 Genetic Associations
with Self-Reported Medical Data, 6 PLOS ONE, no. 8, 2011, at 1, 1–2,
http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0023473.
44. See Paul Wicks et al., Sharing Health Data for Better Outcomes on
PatientsLikeMe, 12 J. MED. INTERNET RES. e19, e21 (2010) [hereinafter Sharing Health Data] (“PatientsLikeMe is a Web-based application where members
explicitly choose to share detailed computable data about symptoms, treatments and health in order to learn from the experience of others and improve
their outcomes.”).
45. See, e.g., Nicholas Eriksson et al., Web-Based, Particpant-Driven Studies Yield Novel Genetic Associations for Common Traits, 6 PLOS GENETICS, no.
6,
2010,
at
1,
1–2,
http://www.plosgenetics.org/article/info:doi/
10.1371/journal.pgen.1000993; Sharing Health Data, supra note 44, at e19–
e20; Paul Wicks et al., Accelerated Clinical Discovery Using Self-Reported Patient Data Collected Online and a Patient-Matching Algorithm, 29 NATURE
BIOTECH. 411, 411–12 (2011) [hereinafter Accelerated Clinical Discovery].
46. SNPTIPS, http://snptips.5amsolutions.com/ (last visited Feb. 8, 2012).
47. See id.
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als a platform to enter their preferences for how their data will
be handled, including who can see it, how it can be used, and
what should be returned to the individual.48 It provides technology solutions for researchers to communicate with participants in trials—including results and incidental finding reporting—all according to the individual’s preferences. The
individuals themselves, not the scientists, determine what is
shared and what is returned.49 Genomera, a small Silicon Valley company, provides a unique platform for individuals to
share genomic and phenotypic information. It is unique because it allows individuals to set up the trials, and they are
aided by the tools the company provides to run and analyze the
trial.50 This system allows on-the-fly return of results, either on
an individual or a group level. None of these examples are traditional return of results or incidental findings. But all of them
point to a growing trend for consumers to expect results—
something that may very well carry over into the biomedical
research arena.
D. RETURN OF RRS AND IFS IN GENOMICS BIOBANKS:
SOMETHING DIFFERENT THAN NON-GENOMIC STUDIES?
There has been much discussion about “genetic
exceptionalism” over the years. This discussion has vacillated
between the premise that there is nothing different about genetic or genomic information and the idea that it is different
and requires different handling, guidance, regulations, and so
on.51 With respect to RRs, some studies show that individuals
do consider genetic information to be different than other medical information, either because it reveals more information
about health risks or because it may have meaning for the participant’s family.52 While familial importance can be implicated

48. Robert H. Shelton, Commentary, Electronic Consent Channels: Preserving Patient Privacy Without Handcuffing Researchers, 3 SCI.
TRANSLATIONAL MED. 69cm4, at 2 (2011).
49. Id.
50. See Ella Dolgin, Personalized Investigation, 16 NATURE MED. 953, 954
(2010); Terry & Terry, supra note 1, at 2.
51. Michael J. Green & Jeffrey R. Botkin, “Genetic Exceptionalism” in
Medicine: Clarifying the Differences Between Genetic and Nongenetic Tests,
138 ANNALS INTERNAL MED. 571, 571 (2003).
52. See Miguel Ruiz-Canela et al., What Research Participants Want to
Know About Genetic Research Results: The Impact of “Genetic Exceptionalism,”
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in any data associated with indication of familial disease, it is
especially obvious in genetic data.53 Green and Botkin examined genetic exceptionalism and found “no clear, significant distinctions between genetic and nongenetic tests justify[ing] a
different approach to testing by clinicians. Nevertheless, with
many genetic tests, the results may cause stigmatization, family discord, and psychological distress.”54
It is true that genetic information may have consequences
for the family, and genomic biobank policies should guide information exchange—even for the relatives of a contributor and
even after the death of that contributor.55 Vos et al. examined
the impact on individuals who were told the results about unclassified variants and uninformative BRCA 1 & 2 testing for
family members.56 The way results were communicated was
significant to family members’ perception of their own cancer
risk.57 Thus, despite some mixed evidence and conclusions, it is
probably safe to say that genetic information at least gives individuals, families, and communities pause, and hence causes
other stakeholders to at least ask if special considerations apply. For the sake of this paper we will restrict comments to IFs
and RRs in genomic biobanks, but realize that many of these
issues are inherent in IFs and RRs in non-genomic research as
well.
E. THE RELATIVITY OF TIME AND CONTEXT
Differences between IFs and RRs are not always clear. For
example, Bovenberg et al. use the term RR to encompass IFs.58
They include results to individuals as well as aggregate results.59 Others are more careful as to the specificity of the
terms as is clearly laid out by Wolf et al.60
6 J. EMPIRICAL RES. ON HUM. RES. ETHICS 39, 40 (2011).
53. See Laura M. Beskow et al., Ethical Issues in Identifying and Recruiting Participants for Familial Genetic Research, 130A AM. J. MED. GENETICS
424, 425 (2004) (explaining the importance of family-based research in a variety of diseases).
54. Green & Botkin, supra note 51, at 571.
55. Bovenberg et al., supra note 2, at 240.
56. Joël Vos et al., Family Communication Matters: The Impact of Telling
Relatives About Unclassified Variants and Uninformative DNA-Test Results,
13 GENETICS MED. 333, 333 (2011).
57. Id. at 339.
58. Bovenberg et al., supra note 2, at 230.
59. Id.
60. Wolf et al., supra note 3, at 364.
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Wolf et al.’s research discovered that many biobanks, studies, and policies recognize a difference between IFs and individual RRs.61 For example, Yale University’s institutional review boards (IRBs) have established policies recognizing that,
in some studies, IFs may be returned but not individuals’
RRs.62 The UK Biobank is time dependent and will offer some
IFs discovered during enrollment (such as elevated blood pressure) to participants but will not offer individual RRs from the
ensuing genetic/genomic analysis. However, once into the research, the UK biobank does not provide individual RR for any
reason.63
Wolf et al. acknowledge that “[s]ome commentators have
questioned the utility of distinguishing between IFs and [RRs],
especially in the context of whole-exome, whole-genome, or genome-wide association studies (GWAS)” and agrees that the
distinction is “fuzziest” in these domains.64 Whole-genome sequencing in clinics provides us an excellent example of the
blurring of research and clinical settings and the distinction between what is an IF and what is an RR. As more systems like
this are built to ascertain correlations in a hypothesisgenerating environment, the differences between RR and IF
will continue to blur. The term biobank will refer to the system
and the stakeholders in it; the terms IF and RR will be used to
describe a range of findings in keeping with Wolf’s definition.
Typically, results are considered RRs, and not clinical results that should be disclosed to participants, because of a lack
of evidence of clinical utility.65 Over time, with the aggregation

61. Id.
62. Id.
63. Id. at 4–5.
64. Id. at 4; see also Laura M. Beskow & Wylie Burke, Commentary, Offering Individual Genetic Research Results: Context Matters, 38 SCI.
TRANSLATIONAL MED. 38cm20, 2 (2010) (explaining that the distinction between RRs and IFs based on “whether the information is related to the study”
is problematic because “[e]ven when the initial study addresses a particular
condition, consent is often requested to store materials for use in unspecified
future research”); Mildred K. Cho, Understanding Incidental Findings in the
Context of Genetics and Genomics, 36 J.L. MED. & ETHICS 280, 281−82 (2008)
(noting that distinguishing IFs from other findings is difficult “because the nature of the genomic research question can be very open ended or descriptive”).
65. Susan M. Wolf et al., Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations, 36 J. L. MED. & ETHICS 219,
231−32 (2008) [hereinafter Wolf, Analysis and Recommendations].
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of increasingly large datasets correlated with clinical information, RRs either become useful clinical results or become irrelevant because they are proven to be insubstantial.66 The increasingly grey line between research and clinical care means
that it is not always possible to determine if something is an
RR or in fact has clinical attributes. Thus something may be an
RR today, and as data is aggregated and analyzed, it may become more meaningful over time. This makes it difficult to create a definitive line before which to determine something is an
RR, and after which something is a clinical result. The information itself can be independent of the system in which it was
obtained, though some would point out that a result cannot be
a clinical result unless it is obtained in a laboratory that is certified by the Clinical Laboratory Improvement Amendments
(CLIA).67 The issue then is one of appropriate infrastructure to
deliver these results.
IFs may be considered such only because they were not the
intent of the study. They can be considered incidental findings
in one context and primary findings in another. Again, the system in which they are discovered may not allow contextualization to play a role, nor provide the infrastructure to deliver the
results. But the results themselves are not the issue. In both
RRs and IFs, what participants believe to be reportable and
what is considered as having clinical utility may be different.
We address this below.
Context and time play a significant role that is difficult to
manage in the strict research context in the integration of genomics into clinical care. When systems exist that allow research and clinical care to cohabitate (as in some emerging programs in research universities collaborating with their health
centers), and information to be aggregated, correlated, and analyzed in real time—in the way that Amazon provides consumer
feedback or TripAdvisor shares restaurant ratings and comments—then the issues that arise as a result of returning RRs
and IFs will be less onerous.
Even when genomic biobanks establish, ahead of any recruiting, a roster of findings that will be reported back, this
should be considered a starting point since ongoing research
will continue to find associations in various populations and for
some individuals. Further, though such advisory boards are
66. See id. at 232−33.
67. See id. at 230.
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recommended and useful, they cannot always determine what
will be important to individuals in reproduction, life, death, or
personal decisions.68
In addition to the meaning of various results changing over
time due to research advances, personal preferences can change
throughout the life course due to many circumstances.69 Needs
change for individuals depending on their personal and familial
circumstances.70 Reproductive planning, healthcare interactions, the diagnosis of oneself or someone in the family, deaths,
and media reports about genetics, genomics and disease, are
among the issues that could alter preferences as to receive research results and incidental findings.
Another aspect of context is related to culture. There are
cultures in which biobanking represents an objectification of
the community, an exploitation of the tribe, or simply part of
something unthinkable, such as the removal, storage, and experimentation on blood or tissue.71
A final contextual aspect is the right not to know. Even
when a biobank has decided certain results are important to
share, an individual may not want to know about the result.72
Though some would say that this right be exercised as long as
it does not cause harm.73 Not suprisingly, recent studies show
that individuals fall in a contiuum of wanting to know, not
wanting to know, and many in the middle want results at least
when they are accurate and actionable.74

68. Wolf et al., supra note 3, at 370.
69. Robert Klitzman, Questions, Complexities, and Limitations in Disclosing Individual Genetic Research, AM. J. BIOETHICS, Nov.−Dec. 2006, at 34, 34–
35; see also Constance A. Griffin et al., Patient Preferences Regarding Recontact by Cancer Genetics Clinicians, 6 FAMILIAL CANCER 265, 269 (2007) (finding that patients wanted to be recontacted with new information regarding a
genetic test for various reasons including information regarding cancer risk to
the patient and relatives, cancer screening, and impacts on the patients’
health).
70. Id., at 35.
71. See, e.g., Michelle M. Mello & Leslie E. Wolf, The Havasupai Indian
Tribe Case—Lessons for Research Involving Stored Biologic Samples, 363 NEW
ENG. J. MED. 204, 204 (2010) (explaining that tribe members objected to use of
their blood samples for various cultural reasons).
72. See Rebecca Bennett, Antenatal Genetic Testing and the Right to Remain in Ignorance, 22 THEORETICAL MED. & BIOETHICS 461, 462 (2001).
73. Id.
74. Bovenberg et al., supra note 2, at 232–33.
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II. TENSION FOR WHOM?
The tension in the system must be considered from numerous viewpoints since any tension is the result of several forces.
These forces will be applied and perceived differently by various stakeholders. Thus, it is not possible to name tensions between practice and policy without examining those from the
perspective of each stakeholder. The key stakeholders, though
there are certainly others, are individual participants, communities, researchers, clinicians, institutions, and society. I write
with a strong bias that all research be participant-centered,
and will therefore call the donors, patients, and contributors of
clinical data and/or samples, participants.
A. PARTICIPANTS
The primary tensions for participants between current policies and practices can be described as arising from expectations, literacy, support, usefulness, and fears.
i. Expectations
When participants enter into a relationship with a genomic
biobank system, they will have expectations.75 In ethics considerations, “expectations are not just neutral facts.”76 They indicate obligations on other individuals or entities to consider
them.77 This might suggest that participants consider the interaction with the biobank to be relational, rather than transactional. I do believe this is the case, given the desire of participants to trust the biobank system and to expect reciprocity
from the whole and its parts.78
Participants’ expectations vary. Certainly the time and
context issues raised above will color expectations. Thus some
participants will expect results, and others will be indifferent. A
fairly large, and increasing, body of research suggests that participants expect to receive some RRs back. For example, in one
Dutch study, between 70% and 88% of what the researchers
called “patients” and “citizens” “probably” or “definitely” wanted results to be communicated to them, dependent on the type

75. Id. at 233.
76. Id. at 238.
77. Id.
78. Herbert Gottweis et al., Connecting the Public with Biobank Research:
Reciprocity Matters, 12 NATURE REVS. GENETICS 738, 739 (2011).
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of results. 79 In this study, questionnaires were given to individuals with asthma, hay fever, or thrombosis (called patients)
and to healthy volunteers (called citizens). Citizens preferred
being informed of research results slightly more than patients.80
Although it sometimes appears that privacy concerns, and
hence how a biobank manages the samples and data they acquire, are most critical when considering whether or not to contribute to a biobank, one study found willingness to contribute
tied to the presence of a binding agreement between the parties
including the return of results.81 Focus group participants in
this study conducted by the Genetics and Public Policy Center
expressed an overwhelming desire for a “contract” with researchers.82 This suggests that the public thinks there should
be reciprocity between researchers and participants.83 Indicative of the diversity in preferences, in the Dutch study referenced above, some participants did not want to be informed of
results.84
As potential participants become increasingly involved and
empowered in health and other aspects of their lives, there may
be expectations that both policies and practices will be consumer focused.85 These participants may expect that the research
enterprise is there to benefit them, and they may not expect either a one-size-fits-all system or one that does not return any
results. Participants may be surprised to find that the research
enterprise doesn’t have a culture of sharing information either
between projects or with participants.86 Participants may expect clear and well-articulated policies that serve the participant.87 Some of the confusion in expectations may relate to an
understanding of what is research and what is clinical care.
Though there is certainly an element of literacy in this aspect,

79. Bovenberg et al., supra note 2, at 233.
80. Id.
81. Juli Murphy et al., Public Perspectives on Informed Consent for
Biobanking, 99 AM. J. PUB. HEALTH 2128, 2132−33 (2009).
82. Id.
83. Id.
84. Bovenberg et al., supra note 2, at 232.
85. See Amy Dockser Marcus, Citizen Scientists, WALL ST. J., Dec. 3, 2011,
at C.1.
86. See id.
87. See, e.g., Murphy et al., supra note 81, at 2132–33.
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it is also probable that many biobank systems do not make the
distinction clear in policy and practice. There is a tacit trust
that the participant is being cared for, particularly in rare disease research.88 And finally, some participants do not want researchers to have results that they themselves do not have.89
ii. Literacy
Participant literacy, or lack thereof, causes a great deal of
tension in the system. A biobank can have well-articulated policies, and then when it implements those policies it may find
that the participants cannot comprehend the policy and/or the
results as the biobank intended. In some genetic testing, participants are educated as to the range of possible findings before
disclosure.90 A number of studies have shown that participants
can lack comprehension of the study in which they are participating.91 Genetic literacy is based on health literacy, which, in
turn, is built on science literacy.92 A 1993 study, repeated with
the same results in 2002, showed that forty-seven percent of
U.S. adults “lack the literacy skills needed to meet the demands of twenty-first century society” defined as having “difficulty locating, matching, and integrating information in written texts with accuracy and consistency.”93 Obviously, if
individuals find it difficult to understand information, then
RRs and IFs will also be difficult to understand.
iii. Usefulness
Usefulness from the participant perspective differs from
the technical definition of clinical utility, which is discussed below in Part II.C. Usefulness simply asks: is this information
useful? For the participant, the answer to that is not a clinical
answer—it takes into consideration all of the issues of time and
88. Henry S. Richardson & Leah Belsky, The Ancillary-Care Responsibilities of Medical Researchers, 34 HASTINGS CTR. REP. 25, 27 (2004).
89. David Wendler & Rebecca Pentz, How Does the Collection of Genetic
Test Results Affect Research Participants?, 143A AM. J. MED. GENETICS 1733,
1736 (2007).
90. See Ellen Wright Clayton, Incidental Findings in Genetic Research
Using Archived DNA, 36 J.L. MED. & ETHICS 286, 289 (2008).
91. E.g., Mary Dixon-Woods et al., Beyond “Misunderstanding”: Written
Information and Decisions About Taking Part in a Genetic Epidemiology
Study, 65 SOC. SCI. & MED. 2212, 2219 (2007).
92. See INST. OF THE NAT’L ACAD., HEALTH LITERACY: A PRESCRIPTION TO
END CONFUSION 146 (Lynn Nielsen-Bohlman et al. eds., 2004).
93. Id. at 6.
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context described in Part I.E above. Generally, participants
consider: (1) how is this information relevant to me, (2) how do
I act on it, and (3) who or what will support me through the actionable steps? Beyond clinical utility, usefulness denotes results that can be meaningful for families and individuals and
communities. These can be related to family lineage, ethnic or
cultural identity, and behavioral traits that could define personal identity for the individual.94
Botkin et al. describe a tension in the system when they
consider that systematic evaluation is a challenge for traditional methods of evidence-based review when considering the
broader impact of genetic tests on the individual, familial and
societal levels, and psychosocial outcomes.95 He describes the
need to consider potential harms and benefits for the participant and the challenge of doing that in the Centers for Disease
Control and Prevention initiated program called Evaluation of
Genomic Applications in Practice and Prevention (EGAPP),
which evaluates genetic tests.96 The issues inherent in individual preferences, and a growing understanding that information
impacts reproductive decision making,97 offspring,98 and eventually other uses, have garnered some attention and are considered by some authors.99 Called “personal utility,” peer reviewed literature is beginning to highlight this participantcentric appraisal of genetic tests.100 Several efforts to reconcile
these tensions have been offered in the form of categorizing
tests, using either a matrix that considers a test’s risk-benefit
94. Vardit Ravitsky & Benjamin S. Wilfond, Disclosing Individual Genetic
Results to Research Participants, AM. J. BIOETHICS, Nov.−Dec. 2006, at 8, 12.
95. Jeffrey R. Botkin et al., Outcomes of Interest in Evidence-Based Evaluations of Genetic Testing, 12 GENETICS MED. 228, 228 (2010).
96. Id. at 229−30.
97. Fabsitz et al., supra note 14, at 578; Wolf, Analysis and Recommendations, supra note 68, at 231.
98. See Susanne B. Haga & Sharon F. Terry, Ensuring the Safe Use of
Genomic Medicine in Children, 48 CLINICAL PEDIATRICS 703, 703−05 (2009).
99. See, e.g., Conrad V. Fernandez & Charles Weijer, Obligations in Offering to Disclose Genetic Research Results, AM. J. BIOETHICS, Nov.−Dec. 2006, at
44, 45–46 (arguing for a broader participant-focused definition of utility).
100. See, e.g., Scott D. Grosse et al., Evaluation of the Validity and Utility
of Genetic Testing for Rare Diseases, in RARE DISEASES EPIDEMIOLOGY 115,
121–27 (Manuel Posada de la Paz & Stephen C. Groft eds., 2010); Ilona M.
Kopitz et al., Willingness to Pay for Genetic Testing for Alzheimer’s Disease: A
Measure of Personal Utility, 15 GENETIC TESTING & MOLECULAR BIOMARKERS
871, 871 (2011).

009 TERRY_PROOF -SK.DOCX (DO NOT DELETE)

2012]

7/5/2012 1:21 PM

TENSION BETWEEN POLICY AND PRACTICE

711

profile against its clinical uncertainty,101 or investigating which
IF’s specialists would recommend returning,102 or using a formal risk-benefit framework for genomic tests that could take
context into consideration.103 A three-tier system has been recommended: Tier 1 “Implement in practice;” Tier 2a “Informed
decision-making in practice;” and Tiers 2b and 3 “Do not use in
practice” (for different reasons).104 Though this doesn’t take
personal utility into consideration, it does begin to provide a
basis for more complex decision making than just yay or nay.
This may begin to resolve the tension in ‘usefulness’. This system, combined with one that gives weight to the preferences of
participants in the context of their lived experience and a vehicle for them to express their preferences, would provide a dynamic solution to the intersection of clinical and personal utility.
iv. Support
A critical tension in the system is support for participants
as they receive, or do not receive, IFs and RRs. This is often
considered from the clinicians’ or the institutions’ point of view.
Discussions about the need for a larger workforce, licensure for
genetic counselors, and/or cost to interpret genomic information—with no clear payment system for information sharing—are common.105 It appears less common to consider this
from the participant perspective. The lack of integration between research and clinical systems creates a gap in which the
participant can fall as they try to navigate information. The
support that participants need in learning of IFs and RRs is
highly variable. Some studies have shown that how information

101. See, e.g., David L. Veenstra et al., A Formal Risk-Benefit Framework
for Genomic Tests: Facilitating the Appropriate Translation of Genomics into
Clinical Practice, 12 GENETICS MED. 686, 691 (2010).
102. See Robert C. Green et al., Exploring Concordance and Discordance
for Return of Incidental Findings from Clinical Sequencing, 14 GENETICS
MED. 405, 406 (2012).
103. See, e.g., Muin J. Khoury et al., Evidence-Based Classification of Recommendations on Use of Genomic Test in Clinical Practice: Dealing with Insufficient Evidence, 12 GENETICS MED. 680, 682 (2010).
104. Id.
105. See, e.g., Wolf, Analysis and Recommendations, supra note 68, at 243
(“Research would be helpful to clarify the types of IFs generated by different
kinds of research, the statistical prevalence of these IFs, the costs of evaluating them and clinical following-up, and the positive and negative impacts on
research participants.”).
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is delivered and by whom is critical.106 Some individuals will
need written materials, some verbal communications, and others general community support with multimedia reinforcement.
Particularly as the evidence develops for various findings, participants are going to need dynamic methods to stay apprised of
the meaning of these findings and how they are relevant or not
to their lives, for example, Private Access, 23andMe, and
PatientsLikeMe.107 This is like being given a very slowly developing Polaroid photograph and keeping it for years, watching
more of the image appear over time. As information becomes
more available, and more or less meaningful, the need for effective support for interpretation, application, and overall management of that information will change. This is a very challenging aspect of RRs and IFs for participants.
v. Fears
1. Discrimination
Individuals could fear discrimination in employment or insurance, even though the Genetic Information Nondiscrimination Act of 2008 (GINA)108 defends the rights of individuals in
the United States in this regard, and comparable laws do this
in other countries.109 Individuals certainly could face discrimination in areas not covered by the law such as long-term care
and disability insurance.110 In one study, individuals who were
worried that study results would be used against them were
less inclined to participate in a hypothetical large-population
study.111 There is a need for further education about GINA for
participants and providers if fear of discrimination is to be alleviated.112
106. Johanna L. Schmidt et al., The Impact of False-Positive Newborn
Screening Results on Families, 14 GENETICS MED. 76, 77–78 (2012).
107. See Terry & Terry, supra note 1, at 2.
108. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110233, 122 Stat. 881 (codified in scattered sections of 26, 29, and 42 U.S.C.).
109. Amy L. McGuire & Mary Anderlik Majumder, Two Cheers for GINA?,
1 GENOME MED. 6.1, 6.1–6.2 (2009), http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC2651591/pdf/gm6.pdf.
110. Id. at 6.2.
111. David J. Kaufman et al, Public Opinion about the Importance of Privacy in Biobank Research, 85 AM. GENETICS 643, 647–48 (2009).
112. Amanda L. Laedtke et al., Family Physicians’ Awareness and
Knowledge of the Genetic Information Non-Discrimination Act (GINA), J.
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2. Lack of Care
A related tension in the system is related to the fact that
there will not only be little information for some IFs and RRs,
but many times these findings are not actionable. Findings
might predict a condition, convey risk, diagnose a condition,
and so on, but across the board, there is a high chance that
there is no treatment based on these findings. Even in the case
of ending the diagnostic odyssey, it has been reported that individuals suffer a loss of confidence in the medical care system.113 In an examination of expanded newborn screening in
California, incidental findings related to diagnosing the mother
appear to leave the family unsatisfied if the family is unable to
act on the information. This may be because the newborn
screening infrastructure is not set up to support treatment for
the mother.114
3. Anxiety Associated with Risk
Early in the personal genomics movement, ethicists considered whether individuals would have increased anxiety as a
result of genetic information and hypothesized that they
might.115 In recent years, some studies suggest that there is
less anxiety over receiving results than previously thought,
though most studies were based on cohorts that availed themselves of counseling.116 Other studies emphasize that the differences in perceptions are based upon the level of counseling
available to the individuals.117 There is a need for more reGENETIC COUNSELING (forthcoming 2012) (e-pub at 7), available at
http://www.springerlink.com/content/r35524617242351l/fulltext.pdf; McGuire
& Majumder, supra note 109, at 6.2.
113. Milica Markovic et al., Embodied Changes and the Search for Gynecological Cancer Diagnosis, 18 MED. ANTHROPOLOGY Q. 376, 387 (2004).
114. Mara Buchbinder & Stefan Timmermans, Newborn Screening and
Maternal Diagnosis: Rethinking Family Benefit, 73 SOC. SCI. & MED. 1014,
1017 (2011).
115. Amy McGuire et al., The Future of Personal Genomics, 317 SCIENCE
1687, 1687 (2007).
116. Katja Aktan-Collan et al., Psychological Consequences of Predictive
Genetic Testing for Hereditary Non-polyposis Colorectal Cancer (HNPCC): A
Prospective Follow-up Study, 93 INT. J. CANCER 608, 611 (2001); Chanita
Hughes Halbert et al., Long-Term Reactions to Genetic Testing for BRCA1 and
BRCA2 Mutations: Does Time Heal Women’s Concerns?, 29 J. CLINICAL
ONCOLOGY 4302, 4305–06 (2011); Kay Wilhelm et al., Issues Concerning Feedback About Genetic Testing and Risk of Depression, 194 BRIT. J. PSYCHIATRY
404, 409 (2009).
117. Sato Ashida et al., The Role of Disease Perceptions and Results Shar-
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search in this area, particularly since there are no studies examining the psychological effects of RR and IF for individuals
who did not chose to be tested. Meanwhile, disparities may be
exacerbated as individuals who can afford testing, and perhaps
unnecessary follow up tests, may ‘raid the medical commons.’118
This impacts communities, which is described in the next section.
B. COMMUNITIES
The tension between policy and practice for communities is
difficult to quantify and even difficult to describe succinctly.
There appear to be a number of questions that need to be asked
in this regard, and no ready answers.
i. How Do IFs and RRs Challenge Community Identity or
Norms?
One must ask if the IFs create some conflict in worldview
vis-à-vis the community or if the identity of the community is
challenged by the RRs or IFs? One can imagine that incidental
findings or research results that are common to the community
could challenge the community’s sense of who it is. This could
be true in an ethnic or geographic community as well as disease-based community. While most of the literature on this
subject is about ancestry, there are also some indications that
having a predisposition to a disease may also threaten a community’s understanding of themselves.119 Blogs and other postings from adolescents with cystic fibrosis (CF) indicate that
‘disease legends,’ akin to urban legends, may arise. For example, some in the CF community have created associations between mutations and classes of severity that do not reflect the
ing in Psychological Adaptation After Genetic Susceptibility Testing: The
REVEAL Study, 18 EUR. J. HUM. GENETICS 1296, 1300 (2010).
118. Amy L. McGuire & Wylie Burke, An Unwelcome Side Effect of Directto-Consumer Personal Genome Testing: Raiding the Medical Commons, 300
JAMA 2669, 2669–70 (2008).
119. Dena S. Davis, Genetic Research & Communal Narratives, 34
HASTINGS CENTER REP. 40, 42 (2004); Carl Elliot & Paul Brodwin, Identity
and Genetic Ancestry Tracing, 325 BRIT. MED. J. 1469, 1471 (2002); Susan
Parry & Carl Elliot, Genetic Ancestry Tracing and American Indian Identity,
AM. PHIL. ASS’N NEWSL. ON PHIL. & MED., Spring 2002, at 12; Mee Lian Wong
et al., Concerns over Participation in Genetic Research Among Malay-Muslims,
Chinese and Indians in Singapore: A Focus Group Study, 7 COMMUNITY
GENETICS 44, 45 (2004).
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currently scientifically validated correlations. Anecdotes in the
community abound trying to use these unfounded correlations
to modulate behavior: “Can I ask ? Is there certain C[F] genes
that are more sever [sic] than others or does it make any difference?”120 This is an area that can use further research. If
groups of people (cities, neighborhoods, affinity groups online,
and church communities) are given IFs and RRs, will they
build their own consensus around the results, determining behavior, and making recommendations? I certainly see individuals beginning to build their own conclusions, without scientific
evidence, in the online Facebook community and in the Chat
listserv I manage for PXE International, which serves the genetic disease pseudoxanthoma elasticum (PXE). One post on
Facebook follows up many claims that fish oil is a good treatment for PXE, which is a disease caused by mutations in
ABCC6—a gene that codes for a membrane transport protein.
The Facebook user posted:
I havent tried [fish oil], but i am getting some tomorrow. Yes Karen, I
am always in pain, my hip joints and knees, They are worse in the
cold. If I walk for a long time too. My gp said my right kneecap is
moving inward and will need an op eventually !!! I am sure it is pxe
related. I also get leg pain all ove,r claudication, i dont like taking
pills so use the ibuprofen gel when it is at its worse xxxx I also get
sore wrists.121

There is no evidence of joint involvement in PXE122 and
certainly no research on fish oil that suggests it would alleviate
any symptoms in the condition. However, the group makes its
own determinations of such matters through reading a small
number of posts from individuals. Even when we repeatedly
point them to layman versions of peer-reviewed published literature, some group members chastise us for not allowing them
to ‘learn from one another.’ This could create a set of communi-

120. Ronnie Sharpe & Mandi Sharpe, RUN, SICKBOY, RUN (June 1, 2011),
http://runsickboyrun.blogspot.com/2011/06/question-from-reader-more-severegenes.html.
121. Karen McDougall & Maria Taggart, PXE International Group,
FACEBOOK
(Dec.
11,
2011,
12:52
PM),
https://www.facebook.com/groups/6236484169/ (errors in the original).
122. Nat’l Ass’n for Pseudoxanthoma Elasticum, Frequently Asked Questions - Pain, PXENAPE, http://www.pxenape.org/faq.htm (last visited Feb. 28,
2012) (responding to the question of whether a person’s joint aches and pains
are a result of PXE, “[A]rthritic symptoms of any kind are not directly related
to or caused by PXE. Mild to moderate joint aches and pains are very common
among the general population . . . [, and] it cannot be said that the cause is
PXE”).
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ty beliefs. While the group members are not basing their
treatments on specific mutations, one can imagine that the
same groupthink would be applied to mutations discovered in
PXE International research projects123 if they were distributed
to the group.
ii. Increased Data Sharing and Comparison Through
Technology
The above examples lead to other questions about the difference between policy and practice in communities. Primarily
one must ask if the sharing of results in online communities
will create fodder for network effect systems to create ecosystems—i.e., can communities create their own data capture and
share and reveal associations beyond what the original research intended? This has been shown to be the case in the
PatientsLikeMe community and to some extent in 23andMe clients. In the PatientsLikeMe community, individuals reported
changes in their behavior based on shared information.124 This
will create other tensions, such as what to do when the practice
of sharing results leads to altered behavior not part of clinical
practice guidelines. There are certainly pros and cons to this
effect.
iii. Obligation to Share IFs and RRs that Are Meaningful for
the Community
Policies about IFs and RRs usually refer to individuals. In
some cases, those results might have meaning for the broader
community, and perhaps should be shared proactively with the
community, possibly in a generalized way. For example, founder effects, increased environmental risk, and strong correlations in a particular genotype would all be candidates for broad
dissemination. A number of researchers recommend engaging
the community in question to help determine return of results
policies.125
123. See, e.g. Ellen G. Pfendner et al., Mutation Detection in the ABCC6
Gene and Genotype-Phenotype Analysis in a Large International Case Series
Affected by Pseudoxanthoma Elasticum, 44 J. MED. GENETICS 621 passim
(2007).
124. See Accelerated Clinical Discovery, supra note 46, at 413.
125. See, e.g., Lainie Friedman Ross et al., Human Subjects Protections in
Community Engaged Research: A Research Ethics Framework, 5 J. EMPIRICAL
RES. HUM. RES. ETHICS 5, 7 (2010); Richard R. Sharp & Morris W. Foster,
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iv. Vulnerable Communities
1. Power Differential When Information Is Not Uniformly
Available to All Parties
The local control of data access may be important to a
community, and this may be difficult if the advisory body is
removed from the community—as is done in some cases—
particularly in large communities such as countries, cities, or
even large university medical centers.126 Further, RR can be
seen as a necessary demonstration of respect and reciprocity for
the community.
2. Potential Discrimination If RRs or IFs in a Group Are
Aggregated
One could imagine that if a SNP purported to be associated
with violence is highly prevalent in a cohort and research results are reported back to a community, that the community
could suffer from aggregate results even if the association lacks
validation. Communities could find results inconsistent with
their beliefs and myths or fear stigmatism as has been reported
by a number of authors.127 Some communities have a difficult
experience during the research process and then choose not to
participate thus limiting the promise of translational medicine.128 This has pros and cons for the community in question—
Grappling with Groups: Protecting Collective Interests in Biomedical Research,
32 J. MED. & PHIL. 321, 325 (2007).
126. See Fabsitz et al., supra note 14, at 577.
127. See, e.g., Ibidapo Akinleye et al., Differences Between African American and White Research Volunteers in Their Attitudes, Beliefs and Knowledge
Regarding Genetic Testing for Alzheimer’s Disease, 20 J. GENETIC
COUNSELING. 650, 656 (2011); Henry T. Greely, Informed Consent and Other
Ethical Issues in Human Population Genetics, 35 ANN. REV. GENETICS 785,
798 (2001); Evaristus A. Nwulia et al., Ethnic Disparities in the Perception of
Ethical Risks from Psychiatric Genetic Studies, 156 AM. J. MED. GENETICS
PART B 569, 578 (2011); LorrieAnn Santos, Genetic Research in Native Communities, 2 PROGRESS COMMUNITY HEALTH PARTNERSHIPS 321, 322–23 (2008)
(describing the objections of the Havasupai Indian tribe after blood samples
taken from members of the tribe were used in a study of schizophrenia, which
the Tribe felt risked stigmatization, and “inbreeding,” which implicated negative cultural beliefs).
128. See generally Ellen Wright Clayton & Lainie Friedman Ross, Implications of Disclosing Individual Results of Clinical Research, 295 JAMA 37, 37
(2006) (explaining that “respect for research participants requires minimizing
harms so that they are not treated as mere means for scientific ends”); Stephanie M. Fullerton et al., Commentary, Meeting the Governance Challenges of
Next-Generation Biorepository Research, 2 SCI. TRANSLATIONAL MED. 15cm3,

009 TERRY_PROOF -SK.DOCX (DO NOT DELETE)

718

MINN. J. L. SCI. & TECH.

7/5/2012 1:21 PM

[Vol. 13:2

they will benefit from retaining power over their information
and samples, but their community may be denied the benefits
of research that may lead to diagnostics and therapies, particularly when those are community specific. In vulnerable communities, offering RRs and IFs could encourage a ‘therapeutic
misconception’— the belief a clinical trial is primarily for therapeutic reasons.129
C. RESEARCHERS
There are some who have written that showing respect to
participants doesn’t necessarily mean giving back results.130
Researchers must concern themselves with analytic validity,
clinical validity, and clinical utility.131 It is beyond the scope of
this paper to discuss the current state of evidence generation to
determine thresholds for each of these steps on the way to integration into clinical practice. As mentioned above, EGAPP and
other efforts are trying to create a formal risk-benefit framework. It is thought that such a framework could offer guidelines for meaningful integration of genomic applications and
avoid premature use of tests with little benefit or health significance.132
The tension in policy and practice is sometimes quite high
for researchers, particularly those that receive samples that
have been de-identified. This is in fact research that is not cov-

at 3 (2010) (noting that “[r]esearch participants often cite a fear of having
their genetic or personal health information used against them should it fall
into the wrong hands”); Michelle M. Mello & Leslie E. Wolf, The Havasupai
Indian Tribe Case – Lessons for Research Involving Stored Biologic Samples,
363 NEW ENG. J. MED. 204, 204–05 (reporting a legal settlement between the
Havasupai Indian Tribe and Arizona State University after blood samples
taken from members of the tribe by the University were used in studies that
the tribe felt violated the scope of their consent); Santos, supra note 127, at
322–23 (describing two specific examples of abuse in genetic research of specific communities, one involving the Havasupai Indians and another multiple
instances of abusive practices involving native Hawaiins).
129. Cho, supra note 67, at 284.
130. Clayton & Ross, supra note 128, at 37; Pilar N. Ossorio, Letting the
Gene Out of the Bottle: A Comment on Returning Individual Research Results
to Participants, AM. J. BIOETHICS, Nov.−Dec. 2006, at 24, 24.
131. Grosse et al., supra note 100, at 116–21.
132. David L. Veenstra et al., A Formal Risk-Benefit Framework for Genomic Tests: Facilitating the Appropriate Translation of Genomics into Clinical Practice, 12 GENETICS MED. 686, 691–92 (2010).
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ered by the Common Rule.133 For example, if policy dictates the
return of IFs and RRs, then the researcher is in an untenable
position with a difficult pathway to accessing enough information to comply with the policy. The Common Rule places
secondary researchers, those using de-identified data or samples, outside of the biobank process, and Wolf et al. note that
many biobanks exist for this purpose.134
Some researchers may well want to be part of the biobank
system and wish to return results, and may in fact have an ancillary obligation toward participants. Others may enjoy the
‘absolution’ that consenting participants imply with agreeing to
the typical terms of no return of research results.135 Researchers, while in a gray area of interaction with participants, unlike
clinicians, do not take a Hippocratic Oath and have no formal
clinical professional codes of conduct.136 In the Dutch study, as
reported above, recall that the citizens and patients wished to
receive findings eighty-five and seventy percent of the time respectively, and ninety-five percent of researchers disagreed
with returning findings.137 It is probable that researchers were
not trained in genomic interpretation, nor did they anticipate
the genomic era in which the line between research and clinical
services would be so blurred. Some argue that withholding clinically important findings may be paternalistic on the part of researchers.138 It is clearly best for both sides to be aware of the
others expectations.
There are a number of considerations for researchers in the
balance between policy and practice.

133. HHS Common Rule, 45 C.F.R. § 46 (2011).
134. Wolf et al., supra note 3, at 364.
135. See generally Bartha Maria Knoppers et al., The Emergence of an Ethical Duty to Disclose Genetic Research Results: International Perspectives, 14
EUR. J. HUM. GENETICS 1170, 1174 (2006) (“[G]enetic information derived
from research is of unknown or uncertain predictive value. Therefore, special
care must be taken to prevent inadvertent release of immature data.”).
136. Dressler, supra note 24, at 87.
137. Bovenberg et al., supra note 2, at 232.
138. See Laura M. Beskow et al., Informed Consent for Population-Based
Research Involving Genetics, 286 JAMA 2315, 2316 (2001); Conrad Fernandez,
Public Expectations for Return of Results—Time to Stop Being Paternalistic?, 8
AM. J. BIOETHICS, no. 11, 2008, at 46, 48; Isaac S. Kohane et al.,
Reestabilishing the Researcher-Patient Compact, 316 SCIENCE 836, 836 (2007).
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i. Balancing Benefit and Risk: How to Assess and from What
Perspective?
As discussed above, the participant has a very different
perspective from the researcher, whose primary goal is to do
excellent science. In a climate of evolving technology, data aggregation, and societal interest in genetic information, it is difficult to determine the weight of benefits and risks. Participants have expectations, and these may not align with each
other or with the researchers conducting the study. Vehicles for
community engagement, coupled with mechanisms for participants to express their RR and IF preferences, would begin to
create a new model for resolving this tension. Rather than reject the current paradigm, citizen scientists and those encouraging participants to have robust agency in the research enterprise, are advocating for a participant-centric system.139 In this
system, the participants’ and researchers’ needs and obligations are in dialogue with one another. One example of a system that will help participants have more power at least in one
direction—enabling their data to be used beyond the initial project for which it has been collected—is the Portable Legal Consent140 created by Sage Bionetworks, Creative Commons,
Kaufman Foundation, Genetic Alliance, and other collaborators.141 This falls short of providing participants mechanisms
for deciding how their data should be used and what should be
returned to them, as is essential in participant-centric research.142

139. See Jane Kaye, The Tension Between Data Sharing and the Protection
of Privacy in Genomics Research, 13 ANN. REV. GENOMICS & HUMAN
GENETICS (forthcoming 2012) (manuscript at page 13) (advocating that researchers “consider new ways of engaging with research participans . . . [t]o do
so respects the dignity of participants and protects fundamental human
rights).
TO
RES.,
140. Draft
Informed
Consent
Form,
CONSENT
http://weconsent.us/consentform (last visited April 10, 2012).
141. See Your Data Are Not a Product, 44 NATURE GENETICS 357, 357
(“[R]esearch participants can contribute their own data under a portable consent . . . [f]rom there, the de-identified data can be accessed by any researcher
who agreed to protect the research subjects and their data under the terms of
the consent.”).
142. See Jane Kaye et al., From Patients to Partners: Participant-Centric
Initiatives in Biomedical Research, 13 NATURE REV. GENETICS (forthcoming
2012).

009 TERRY_PROOF -SK.DOCX (DO NOT DELETE)

2012]

7/5/2012 1:21 PM

TENSION BETWEEN POLICY AND PRACTICE

721

ii. Returning Findings Are Time and Resource Intensive: How
to Pay for Such Activities?
It can be quite costly on many levels to disclose results,
and some are concerned that those resources of time and money
should be used for the research enterprise.143 However, others
simply ask the question of how it will be weighed in the assessments that need to be done both in creating policies and in
determining practice.144 Once the decision to return results has
been made, the logistics of recontacting is not trivial in the current systems. If, as is thought by some, participants decide they
want results returned, then systems will have to be built that
will allow such preferences.145 In addition, if there is a ‘right
not to know,’ then these systems must allow sufficiently complex preferences and also allow them to change over time. It is
not even easy to contact individuals with preliminary IF results
that require verification, since that in itself reveals some result
that may require genetic counseling or other follow-up.146 Further follow-up for these individuals may burden the health care
system with requests for diagnostic procedures that lack a
sound basis.147 Individuals with different levels of literacy will
require different levels of support, which will require varying
methods of education and a sundry of follow-up activities. It
will be easy for individuals who do not have the right kind of
support and follow-up to ‘raid the medical commons.’
iii. Misconceptions Are Easy to Come by: How Can We Address
Them to Allay Concerns?
There is a concern articulated by many authors that participants could suffer from ‘therapeutic misconception’ and researchers might be inclined to overstate the benefits of enrollment.148 Are the researchers confused as well, or at least

143. Paul Affleck, Is It Ethical to Deny Genetic Research Participants Individualised Results?, 35 J. MED. ETHICS 209, 212 (2009); Griffin et al., supra
note 69, at 270.
144. See Fabsitz et al., supra note 13, at 577.
145. Affleck, supra note 143, at 212.
146. Cho, supra note 67, at 284.
147. Bovenberg et al., supra note 2, at 232.
148. Laura M. Beskow, Considering the Nature of Individual Research Results, AM. J. BIOETHICS, Nov.−Dec. 2006, at 38, 38 (2006); Clayton & Ross, supra note 128, at 37; Fernandez, supra note 138, at 47; Bartha Maria Knoppers
& Claude Laberge, Return of “Accurate” and “Actionable” Results: Yes!, 9 AM.
J. BIOETHICS, June–July 2009, at 107, 108; Ossorio, supra note 130, at 25.
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perhaps lack the ability to communicate results to the participants?149 It is not usually the activity of researchers to communicate results, and so miscommunication is highly probable.150
iv. Communicating with Participants Can Be Quite
Complicated: How Can We Do This?
Clinicians can fall back on a defined relationship complete
with a code of conduct, but researchers do not have this luxury.
There is usually not an obvious or ready set of mores for this
interaction. What if the participants require ancillary care—
care beyond that required to carry out the research safely—how
can this be done in a meaningful and utilitarian manner?151
Though the relationship between researchers and participants
is not meant to be therapeutic, or clinical,152 one can ask of researchers: If they thought that there was no health benefit,
then why subject the individuals to the research in the first
place? Thus, even researchers may be entering into a compact
with participants that, though not traditionally considered bilateral, are a priori also in a relational interest to the participant.
D. CLINICIANS
Clinicians, like researchers, are in the middle of the tension between policy and practice, since they will be among
those who must administer the policy while following formal
and informal practice guidelines. The clinician may raise several issues from his or her perspective.

149. See Fiona A. Miller et al., When Research Seems Like Clinical Care: A
Qualitative Study of the Communication of Individual Cancer Genetic Research Results, 9 BMC MED. ETHICS 1, 2 (2008), available at
http://www.biomedcentral.com/content/pdf/1472-6939-9-4.pdf.
150. Lynn G. Dressler & Eric T. Juengst, Thresholds and Boundaries in the
Disclosure of Individual Genetic Research Results, AM. J. BIOETHICS,
Nov.−Dec. 2006, at 18, 19.
151. Henry S. Richardson, Incidental Findings and Ancillary-Care Obligations, 36 J.L. MED. & ETHICS 256, 268 (2008).
152. Teri A. Manolio, Taking Our Obligations to Research Participants Seriously: Disclosing Individual Results of Genetic Research, AM. J. BIOETHICS,
Nov.−Dec. 2006, at 32, 33.
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i. I Lack the Resources to Educate the Participant
Clinicians may well ask: If I don’t understand (or agree
with) the implications of the finding myself, how will I describe
it to my patients? Clinicians are challenged in interpreting genetic tests, which are becoming increasingly available through
both clinical practice settings and through direct-to-consumer
marketing.153 Though they are becoming more ubiquitous, more
often than not their clinical utility (for the clinician) or usefulness (for the participant) is not evident. Individuals troll the
web and bring stacks of printed material from websites to office
visits with clinicians, and clinicians are usually not as familiar
with this material to even determine its appropriateness.154
Adding the reporting of RRs and IFs to these challenges will
create additional burden for clinicians. Clinicians will also be
faced with either conflicting, or at least nuanced, policies for issues related to results for minors, which will have implications
for other family members and the potential need for follow-up
counseling.
ii. I Have X Minutes per Visit. How Am I Going to Find Time to
Deal with This?
With the burden of enormous numbers of tests becoming
available, as well as the potential to be required to share RRs
and IFs, already time-crunched clinicians will not be able to
find the time to advise patients or participants. The current
medical reimbursement system, particularly in the United
States, does not generally pay for information exchange or
counseling.
iii. This Is My Patient, but I Have to Share Him/Her with a
Researcher. How Do I Navigate This Complex Relationship?
If a biobank participant is recruited into a biobank by their
clinician, and a researcher is using the data and samples, then
there will be a complex set of relationships for the clinician to
navigate. Deciding what should be reported, though potentially
determined by policy at local institutions and the biobank, will
be complex in practice. Determining how to report the findings
and what to do about follow-up will require coordination that
may not be present in the currently available infrastructure or
153. Joshua L. Deignan & Wayne W. Grody, Ordering Genetic Tests and
Interpreting the Results, 70 ADVANCES OTO-RHINO-LARYNGOLGY 18, 18 (2011).
154. Botkin et al., supra note 95, at 228–29.
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protocols between clinicians and researchers. Some have suggested that these relationships can be sorted out effectively, for
example, by allowing others in the team, not the principal researcher, give results to participants.155
E. INSTITUTIONS
When institutions put policies into practice the infrastructures’ needs and necessary protocols may be onerous and/or
costly. Kohane et al. recommend an electronic system that will
take into account preapproved ‘returnable findings’ and participant preferences.156 Most institutions require human interfaces, usually with genetic counselors. For example, the ClinSeq
project at the National Human Genome Research Institute
(NHGRI) uses healthcare professionals to report information
back to participants when such information fits criteria they
have determined for disease-causing variants.157 Others have
debated what and when to reveal to patients. The Coriell Personalized Medicine Cooperative returns findings to individuals,
differentiating risk on genetic and non-genetic factors.158 The
REVEAL Study, which focused on reporting apoliprotein E
(APOE)159 status to individuals, studied the psychological issues related to risk for Alzheimer’s disease and the effects of
results being reported to individuals.160
Institutions will need to consider how to conduct informed
consent in a way that allows compliance with policies that require RRs and IFs to be returned. Wolf et al. recommend that
biobanks (and therefore the institutions or organizations that
determine policy for them) take several steps to assist in this
process:

155. Fernandez, supra note 138, at 47.
156. Kohane et al., supra note 138, at 836.
157. Leslie G. Biesecker et al., The ClinSeq Project: Piloting Large-Scale
Genome Sequencing for Research in Genomic Medicine, 19 GENOME RES. 1665,
1671 (2009) (“ClinSeq is a pilot project to investigate the use of whole-genome
sequencing as a tool for clinical research.”).
158. Stack et al., supra note 34, at 134 (“[C]onsented participants provide
saliva samples, which are genotyped . . . . Using a secure web-based portal, the
CPMC provides participants with . . . personalized results for potentially actionable health conditions.”).
159. APOE is a susceptibility gene linked with Alzheimer’s Disease. Ashida
et al., supra note 117, at 1296–97.
160. Id. at 1297.
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[B]iobanks should make sure that primary researchers (or collection
sites) specify how they plan to handle the issue of IFs and [RRs], and
indicate that they have consulted their IRB in erecting this plan.
Biobanks will need to establish an agreement with primary researchers (or collection sites) on the respective roles the biobank and primary research (or collection site) will play in the CARR process. Together
they will need to consider whether key codes will be housed not just
at the primary research (or collecting) institution but also at the
biobank or trusted intermediary . . . .161

Implementing this process will be easier for biobanks being
built from the ground up than for those already in existence.162
It may be difficult for institutions to set institution-wide
principles, particularly since different departments may view
both the process of sharing RRs and IFs and the specific determinations of what is shared in different ways depending on
their sensitivity to the information, sophistication about genetic
and genomic information, culture of the disciplines they represent, and sensitivity to the vulnerabilities of their populations
and/or clients.163
It will be important to educate the institutional review
boards (IRBs) associated with the institution. A recent study
showed that IRBs find oversight challenging as the terrain becomes more complex.164 At the very least these entities need to
consider whether results are from CLIA certified laboratories,
since some research results are certainly not performed in these labs.165 If not performed in an appropriate lab, the findings
will need to be validated in a CLIA lab, and the institution will
probably incur costs for this further testing.166
In 1999, the National Bioethics Advisory Commission
(NBAC) put forth some recommendations on the subject:
IRBs should develop general guidelines for the disclosure of the results of research to subjects and require investigators to address the-

161. Wolf et al., supra note 3, at 379.
162. See Terry & Terry, supra note 1, at 1–2 (noting that there are several
problems with the old system).
163. See generally Ashida et al., supra note 117, at 1299 (noting that reporting genetic problems can affect health).
164. Amy A. Lemke et al., Broad Data Sharing in Genetic Research: Views
of Institutional Review Board Professionals, 33 IRB: ETHICS & HUM. RES. 1, 4
(2011).
165. See James O. Westgard, Charts of Operational Process Specifications
(“OPSpecs Charts”) for Assessing the Precision, Accuracy, and Quality Control
Needed to Satisfy Proficiency Testing Performance Criteria, 38 CLINICAL
CHEM. 1226, 1226 (1992) (“These CLIA PT criteria describe limits for the ‘total
error’ ascribable to the imprecision and inaccuracy of the testing process.”).
166. See Wolf et al., supra note 3, at 371.
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se issues explicitly in their research plans. In general, these guidelines should reflect the presumption that the disclosure of research
results to subjects represents an exceptional circumstance. Such disclosure should occur only when all of the following apply:
a) the findings are scientifically valid and confirmed, b) the
findings have significant implications for the subject’s health concerns, and c) a course of action to ameliorate or treat these concerns is readily available . . . . When research results are disclosed to a subject, appropriate medical advice or referral should
be provided.167 In 1999, these were appropriate guidelines for
IRBs. I am not sure that in the past twelve years, IRBs have created the policies that were needed—in some ways these recommendations were very forward looking. The second sentence,
however, belies the age in which these were written—they state
that going forward, disclosing research results will be “an exceptional circumstance.”168 Were these written today, they would be
more direct and specific; particularly because the quality and relevance of the data generated by whole genome sequencing, which
is now a much more common occurrence, requires clear disclosure
policies.169

Perhaps the greatest tension for institutions will come
from engaging participants as true participants in the process.
Institutions and their IRBs—which are created to focus on protecting research participants—are not built on a relationshipbased engagement model.170 In my work on biobanks for both
single diseases and multiple diseases, I have built a relationaltrust model in which the biobank is steward for the participants in which the actual community owns and manages the
biobank.171 David E. Winickoff suggests that this is indicative

167. NAT’L BIOETHICS ADVISORY COMM’N, RESEARCH INVOLVING HUMAN
BIOLOGICAL MATERIALS: ETHICAL ISSUES AND POLICY GUIDANCE vi−vii (2000),
available at http://bioethics.georgetown.edu/nbac/hbm_exec.pdf.
168. Id.
169. Jane Kaye et al., Ethical Implications of the Use of Whole Genome
Methods in Medical Research, 18 EUR. J. HUM. GENETICS 398, 402 (2010).
170. See Lemke et al., supra note 164, at 1 (outlining the IRB role of informing patients).
171. Sharon F. Terry et al., Advocacy Groups as Research Organizations:
The PXE International Example, 8 NATURE REVS. GENETICS 157, 160 (2007)
(noting the successes in information gathering and research of such
partnerships); Sharon F. Terry & Charles D. Boyd, Researching the Biology of
PXE: Partnering in the Process, 106 AM. J. MED. GENETICS 177, 180–81 (2001)
(describing the formation and new model of a genetic disease organization); cf.
David C. Landy et al., How Disease Advocacy Organizations Participate in
Clinical Research: A Survey of Genetic Organizations, 14 GENETICS MED.
(forthcoming 2012) (e-pub at 4–5) (discussing the potential pressures to
participate that can stem from such organizations).
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of a shift from benefit sharing, common in the biobanks created
by research institutions, to power sharing:
[L]ooking at the situation prior to donation and the transfer of entitlement, the group of donors as a collective possesses a crucial form of
material, informational and biological capital that could be used to
demand a share of power. This is one of the insights to be drawn from
the PXE International story, where disease group members formed
and retained legal control of a biobank in order to help advance the
particular research goals of the organization.172

Though the focus of this paper is not this paradigm shift, I
believe it has implications for institutions that engage in
biobanking. The idea that the individuals donating samples
and data to biobanks might share in the power creates new
mechanisms for decision making about what results are returned, how they are returned, and when they are returned.173
This shift, since it will be part of what institutions need to consider, will be challenging, particularly for academic medical
centers, which historically have tended toward a hierarchy that
does not lend itself to such robust community engagement or
participant-centered research.174
F. SOCIETY
There is some debate about whether biobanks serve society
or serve the research community more.175 If, in fact, they serve
society, then society should have a role in the policy setting and
execution of practice in RRs and IFs. There is no simple mechanism to increase participation, but the discussion about literacy above is relevant here for society as well. The engagement of
society in biobanking in general could increase public interest
in biomedical research, increase public literacy, and create

172. David E. Winickoff, From Benefit Sharing to Power Sharing:
Partnership Governance in Population Genomics Research 13 (Oct. 3, 2008)
(working paper) (on file with Ctr. for the Study of L. & Soc’y Jurisprudence &
Soc. Pol’y Program), available at http://escholarship.org/uc/item/845393hh#.
173. See Terry et al., Advocacy, supra note 171, at 160 (“The coordination of
research by PXE International allowed the continued aggregation of both negative and positive findings, and dissemination of those results.”).
174. Kieran C. O’Doherty et al., From Consent to Institutions: Designing
Adaptive Governance for Genomic Biobanks. 73 SOC. SCI. MED. 367, 367–68
(2011).
175. See Susan M.C. Gibbons et al., Lessons from European Population
Genetic Databases: Comparing the Law in Estonia, Iceland, Sweden and the
United Kingdom, 12 EUR. J. HEALTH L. 103, 122 (2005) (noting the distinct
interests of informing participants and sharing research with the scientific
community).
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more active involvement overall.176
Questions about public health are inherent in societal perspectives on returning RRs and IFs because “[t]he central moral concern of public health ethics is to specify the conditions
that warrant paternalistic interventions that override individual autonomy to prevent people from adopting unhealthy behaviors.”177
If society becomes more literate, more engaged, and has a
role in determining the return of RRs and IFs reporting, then
we must also consider what else might change.178 For example,
would the relatively paternalistic relationship of researchers
and patients become more equal?179 If participants feel more
engaged in the research enterprise, would some of the power
differential be reduced?180 It is important to consider what
would become of the clinical trial compact if society and communities were more involved in decision-making about research. Already, some of the social networking sites have altered the clinical trial compact.181 Individuals can share
information about the trial, potential treatments, and the pros
and cons of placebos in such a way that trials are not truly
blind, or worse, they are hard to recruit for.182 Several years
ago, when antiangiogenesis therapies for macular hemorrhaging became available for common condition macular degeneration, PXE International wanted to do a trial of the new therapy
against the existing laser therapy. It was impossible to enroll in
176. Richard R. Sharp & Morris W. Foster, Clinical Utility and Full
Disclosure of Genetic Results to Research Participants, AM. J. BIOETHICS,
Nov.−Dec. 2006, at 42, 43.
177. M. Sutrop, Viewpoint: How to Avoid a Dichotomy Between Autonomy
and Beneficence: From Liberalism to Communitarianism and Beyond, 269 J.
INTERNAL MED. 375, 375 (2011).
178. See Sharp & Foster, supra note 176, at 43.
179. See Terry & Boyd, supra note 171, at 179 (discussing an anecdote
where researchers took a sample without an informed consent procedure).
180. See generally Sharp & Foster, supra note 176, at 43–44 (explaining
that informing patients can empower them to make better choices for their
health).
181. See Accelerated Clinical Discovery, supra note 45, at 411–12 (detailing
research of drug effectiveness through the use of an online forum and a specialized control matching algorithm).
182. See generally A.D. Farmer et al., Social Networking Sites: A Novel
Portal for Communication, 85 POSTGRADUATE MED. J. 455, 456–58 (2008) (discussing the sharing that occurs on social networks between people suffering
from the same disease).
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such a trial because, using mechanisms PXE International had
built for community sharing, individuals experiencing hemorrhaging went to their retinologists and requested
antiangiogenesis treatments. There were no participants left
for a clinical trial. This could become more widespread, and the
way clinical trials are conducted might have to be restructured.183
With the emergence of new technologies comes something
termed “network effect.”184 As the number of people who participate in technology increases, the benefit increases.185 As participation increases, changes also occur in the industries, technologies, and communities around the new technology.186 A
veritable ecosystem of independent solutions and improvements on the original arise.187 For returning RRs and IFs, it
will be easier to offer society a role as new technologies arise.
We have witnessed similar increases in participation in
numerous other “long tails” in other previously hierarchical industries.188 Individuals share information via websites and
apps such as Craigslist, Angie’s List, Amazon, Facebook, and
iTunes, revolutionizing how consumers have interacted with
markets and each other. 189 The Arab uprising was certainly

183. See Accelerated Clinical Discovery, supra note 45, at 412 (describing
one way that researchers conducted a clinical trial when presented with a
community that was already participating in a treatment).
184. Garth Saloner & Andrea Shepard, Adoption of Technologies with Network Effects: An Empirical Examination of the Adoption of Automated Teller
Machines, 26 RAND J. ECON. 479, 479–80 (1995).
185. Id. at 480 (“[A]s the number of people who make and receive calls increases, each individual can communicate with more people . . . . [E]ach new
user confers a benefit on all other users.”).
186. See Michael L. Katz & Carl Shapiro, Network Externalities, Competition, and Compatibility, 75 AM. ECON. REV. 424, 425 (1985) (noting that firms
can make a choice about how to compliment the network effect).
187. See Venkatesh Shankar & Barry L. Bayus, Network Effects and Competition: An Empirical Analysis of the Home Video Game Industry, 24
STRATEGIC MGMT. J. 375, 376 (2003) (noting that there is still competition to
improve and innovate in network effect markets).
188. See The Economist Online, Blockbuster Files for Bankruptcy: From
Blockbuster
to
Turkey,
ECONOMIST
(Sept.
23,
2010),
http://www.economist.com/blogs/newsbook/2010/09/blockbuster_files_bankrupt
cy/print (discussing how Blockbuster was pushed out in part due to the success
of Netflix).
189. See John Seely Brown & Richard P. Adler, Minds on Fire: Open Education, the Long Tail, and Learning 2.0, EDUCASE REV. Jan.–Feb. 2008, at
17, 26–27 (noting that the internet offers an opportunity to change education
by uniting people with interests in narrow disciplines).
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aided by Twitter; traditional power structures cannot withstand the power of people.190 Consider the example of Waze, a
smartphone app that has the tagline “Outsmarting Traffic, Together.”191 It allows travelers to input police presence, radar,
disabled cars, traffic, and other notable activities along one’s
travel route, thus giving other users warning about what to expect—even speed traps!192 As noted above, crowdsourcing medical information with resources like 23andMe, Private Access,
PatientsLikeMe, Genomera, and Althea’s Crowd Sourced Longitudinal Studies have the potential to change the paradigm of
participation in biomedical research.
III. CONCLUSION
A. POTENTIAL SOLUTIONS FOR KEY CHALLENGES
The tensions between policy and practice for biobanks RRs
and IFs must, and can be, alleviated to some degree. The goal,
as mentioned in the introduction, is not to exacerbate these
tensions but instead to understand them from the perspectives
of a variety of stakeholders in a variety of contexts.193 Once understood, the applicable systems can be optimized to increase
overall health and advance biomedical research. If the entire
enterprise was built on a relational model rather than a transactional one, many of the disconnects would either be relieved
or workable in the context of evolving relationships.194 “[T]he
lack of personal contact (visual, verbal, or otherwise) with a
participant does not diminish the participant’s stake in the results or the researcher’s responsibility to consider the value of
the research finding could have for the research participant.”195
Certainly some of the processes must be codified protocols that
190. Peter Beaumont, The Truth about Twitter, Facebook and the Uprising
(Feb.
24,
2011),
in
the
Arab
World,
GUARDIAN
http://www.guardian.co.uk/world/2011/feb/25/twitter-facebook-uprisings-arablibya (noting that social media had varying but important effects in the revolutions across the Arab world).
191. WAZE, http://www.waze.com/ (last visited Feb. 9, 2012).
192. About Us, WAZE, http://www.waze.com/about/about_us/ (last visited
Feb. 9, 2012).
193. See supra Figure 1.
194. See Sharp & Foster, supra note 176, at 43.
195. Lynn G. Dressler & Eric T. Juengst, Thresholds and Boundaries in the
Disclosure of Individual Genetic Research Results, AM. J. BIOETHICS, Nov.–
Dec. 2006, at 18, 18–19.
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are immutable, and all processes must be based in carefully
thought out policies; however, the execution of these policies
and procedures should be relationally based. This has been said
quite well by Lynn G. Dressler:
DNA and other human specimen banking coupled with studies in genetic and genomic research highlight the need to transition to a more
socially responsible standard of research conduct in biomedicine. We
need a deliberative process to address the roles and responsibilities of
biobankers and researchers to inform the development of “codes of
conduct.” This process must address the tensions between moral intuition and professional boundaries so the resulting codes are broad
enough to allow for moral analysis and yet narrow enough to provide
some boundary for decision-making. This would require moving toward a collaborative process for decision-making, with a strong involvement by the community and contributors to the biobank, not just
the professional or regulatory groups.196

The current provider-patient relationship is built on paternalism.197 Moving to a partnership will allow relationships
built on beneficence rather than rights. Unlike paternalism,
beneficence is not in conflict with the autonomy called for by
various bioethics policies.198 In closing, there are a number of
areas where careful consideration would alleviate some of the
challenges described above.
i. Reidentification
Wolf et al. note three different solutions to alleviate the
challenges associated with reidentification: (1) primary researchers could reidentify participants when needed; (2) the
biobank itself could hold the key to reidentification; or (3) they
could rely on a “trusted intermediary” or “honest broker” to
hold the key and reidentify.199 It is possible, as is the case for

196. Dressler, supra note 24, at 96–97.
197. Fernandez, supra note 138, at 46–47.
198. O’Doherty et al., supra note 174, at 372 (noting that increased
participation by disease communities actually does not have a negative effect
on the formation of biobank despite widespread knowledge of related
concerns).
199. Wolf et al., supra note 3, at 375–76. The disclosure process is best
served if a strategy is decided at the onset of the project instead of when
problems emerge. Mark A. Rothstein, Tiered Disclosure Options Promote the
Autonomy and Well-Being of Research Subjects, AM. J. BIOETHICS, Nov.–Dec.
2006, at 20, 21 (advocating for patients to be given a range of disclosure
options); Rihab Yassin et al., Custodianship as an Ethical Framework for
Biospecimen-Based Research, 2010 CANCER EPIDEMIOLOGY BIOMARKERS &
PREVENTION 1012, 1012 (emphasizing that transparency can possitively affect
the relationship between researchers and patients).
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the Genetic Alliance Registry and BioBank,200 for the biobank
to be the trusted intermediary.201 There are electronic solutions
being considered to alleviate the burden and complex challenges of varied preferences in different contexts.202
ii. Participant-Centricity
Partnerships between researchers and participants could
be a core around which robust biomedical research could be developed, and offering participants the results from research
could cement that relationship.203 A more participant-centric
engagement will alleviate some of the tensions and help to define the solutions that are required.204
A major attribute of biobanks becoming participant-centric
is recognition of the context in which people make decisions
and the dynamic nature of contextual decision-making.205 For
this reason, biobanks must make it easy for participants to
modify their preferences.206 Technology solutions can offer flexibility and the opportunity to customize one’s preferences to the
state of one’s life, including the immediate needs of the participant and their family.207

200. About BioBank, GENETIC ALLIANCE REGISTRY & BIOBANK,
http://www.biobank.org/english/View.asp?x=1360 (last visited Feb. 9, 2012).
201. Wolf et al., supra note 3, at 80; see also Jimmie Vaught et al., An NCI
Perspective on Creating Sustainable Biospecimen Resources, 2011 J. NAT’L
CANCER INST. MONOGRAPHS 1, 2 (2011) (noting that the National Cancer Institute has identified ethical and legal requirements in addition to other best
practices).
202. Kohane et al., supra note 138, at 836–37.
203. See Grégoire Moutel et al., Communication of Pharmacogenetic
Research Results to HIV-Infected Treated Patients: Standpoints of
Professionals and Patients, 13 EUR. J. HUM. GENETICS 1055, 1059 (2005)
(identifying the potential positive effects of informing patients participating in
long-term studies).
204. Id. (noting that withholding information can lead to anxiety).
205. See Wolf et al., supra note 3, at 380 (explaining that biobanks could
participate in the disclosure process).
206. Bovenberg, supra note 2, at 234 (explaining that biobanks can ease
the process by regularing meeting with participants and using the internet to
communicate changes); see also Knoppers et al., supra note 135, at 1173
(“[P]ublishing clinical research results in a scientific journal or in a regulatory
database is no longer ethically sufficient. The ethical principles of respect for
the person, beneficence and justice obligate the researcher to offer results in a
manner that is clear and understandable to the research participants.”).
207. See Bovenberg, supra note 2, at 234 (noting that the internet can help
people make changes to disclosures); Kaye, supra note 142.
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If biobanks were established primarily in the service of
participants, then decision-making would be easier.208 It might
also be said that it would be harder to conduct objective research in the service of science—science that will lead to the solutions the participants may desperately need.209 This is probably true but not a reason to move participant interests to the
side or to demote them. It is also true that a sophisticated system can offer participants the choice to donate their sample to
be used for any and all research with no strings attached, expressing no desire for the return of RRs and IFs.210
iii. Expense/Cost
There is great concern that there is no reasonable way to
pay for complex consenting systems that would allow participant preferences to determine the return of research results
and incidental findings.211 One need only consider the current
social network systems, including the inexpensive nature of
such systems, to imagine comparable systems for the research
world. Facebook, with a network of around 800 million individuals, representing the third largest country on the planet (only
smaller than China and India), started on a couple of computers in a dorm room.212 Craigslist, with more than 20 billion
page views per month, began as a listserv by Craig Newmark
when he was new to San Francisco and trying to find events in
the city.213 Of course, these systems now have whole economies,
largely based on advertising or subscriptions, connected to
them to enable the build outs, expansions, and improvements
we all have come to expect. While there is a great fear of what

208. See Wolf et al., supra note 3, at 378.
209. Landy, supra note 171, at 4–5 (noting that there are problems with
disease advocacy organizations, the parent groups that run some biobanks);
see supra Part II.F. (explaining the problem with antiangiogenesis therapies
on conducting clinical trials for a small disease community).
210. See Rothstein, supra note 199, at 21 (advocating a tiered approach
that lets patients make a choice about disclosure and the length of the term of
use of genetic samples).
211. See Moutel, supra note 203, at 1059.
212. See Don Reisinger, Facebook Six Years Later: From a Dorm Room Experiment to a Household Name, L.A. TIMES, Feb. 4, 2010,
http://latimesblogs.latimes.com/technology/2010/02/facebook-six-years-laterfrom-a-dorm-room-to-a-household-name.html.
213. See On the Record: Craig Newmark, S.F. CHRON. (Aug. 15, 2004),
http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2004/08/15/NEWMARK.TMP
&ao=all.
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advertising might do to biobanking, clinical trials, and biomedical research in general, it is possible to maintain authentic and
transparent systems without endangering the core mission.214
The public can distinguish to some extent between authentic
and inauthentic network tools.215 In addition, because most of
these interactions are virtual, new tools will be needed to supplement the ones people already use to discover inauthenticity.
Currently, there are researchers working on algorithms to detect fake reviews; for example, a team at Cornell has published
a possible method for such screenings.216
It is possible that the costs for creating and maintaining
systems that allow individuals to detail how and when they
want results to be reported back to them can be built into
grants.217 It is also a certainty that the cost of such systems will
decrease over time.218 In an analogous information technology
example, when I built a shopping cart to take donations on the
PXE International website in 1997, it cost me hundreds of
hours of coding work. Now I can add a robust shopping cart
free, with no design, build, installation, or transaction fees.
This was unthinkable a few years ago. A whole ecosystem has
been built around these tools, and the tools themselves cost
very little to nothing now. The same can happen with emerging
software such as Private Access;219 Bio-PIN;220 an ‘intelligent’

214. Rothstein, supra note 199, at 21.
215. Cf. Moutel, supra note 203, at 1059 (noting that patients wanted to
view results even if they did not have the technical science background to accurately interpret the results).
216. Myle Ott et al., Finding Deceptive Opinion Spam by Any Stretch of the
Imagination, in PROCEEDINGS OF THE 49TH ANNUAL MEETING OF THE
ASSOCIATION FOR COMPUTATIONAL LINGUISTICS: HUMAN LANGUAGE
TECHNOLOGIES 309, 309 (2011) (researching filtering of opinion spam for
websites such as Yelp and TripAdvisor).
217. Fernandez, supra note 138, at 48.
218. See William E. Evans & Mary V. Relling, Moving Toward Individualized Medicine with Pharmacogenomics, 429 NATURE 464, 468 (2004)
(“[A]dvances in technology will drive down the cost of genotyping sooner than
science and medicine will be able to establish definitive polygenic models for
optimizing drug therapy.”).
ACCESS,
INC.,
219. About
Us,
PRIVATE
https://www.privateaccess.info/about-us/ (last visited Feb. 9, 2011) (“Private
Access, Inc. has developed a transformative consumer-centric technology
platform that permits internet search for private information.”).
220. J.J. Nietfeld et al., The Bio-PIN: A Concept to Improve Biobanking, 11
NATURE REVS. CANCER 303, 304 (2011) (“The Bio-PIN concept is based on the
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cancer risk protocol;221 the UK BioBank,222 which considers
consent as an ongoing process; and others. As Fullerton et al.
put it: “It is time to acknowledge that first-generation technical
and regulatory solutions are not up to the task of addressing
the ethical and scientific challenges of next-generation
biorepository research.”223
B. THE MOVEMENT TOWARD OPEN DATA SHARING
Some have called for a new ethical framework on collective
values.224 There is a broad movement towards data sharing
that is changing our values. The current biomedical research
culture was built on a 19th century model of win, lose, and
completion.225 As this culture evolves, impacted by the current
cultural mores of open access and data sharing, it will enable
relational, partnership-based, solutions. Until it evolves (and it
may do so kicking and screaming in some quarters), there will
be some enormous tensions in the system. At the same time, as
some suggest, academic medical centers can take a lead in this
regard.226 It is critical that all of the stakeholders are engaged
in this culture shift.227 Participants must take a proactive role
in partnering, with all of the inherent and concurrent responsibilities and benefits. The tension in the system is a beacon of
light that allows great clarity if all stakeholders are empowered
to look carefully at the land between policy and practice in returning results. This tension can spur innovation if all stakeholders work for the benefit of the ultimate goal: better health.
There will be risks for all entities involved, but the benefits will
principle that from each individual a unique distinguishing biological
characteristic (DBC) can be derived that is present in every sample of
biological material from that individual.”); J.J. Nietfeld et al., The Flexibility of
Biobanking with the Bio-PIN System, 11 NATURE REVS. CANCER 895, 895
(2011) (“The Bio-PIN system is flexible. It enables donors and biobanks to
communicate in a secure way . . . .”).
221. See J. Scott Roberts et al., Returning Individual Research Rresults:
Development of a Cancer Genetics Education and Risk Communication
Protocol, 5 J. EMPIRICAL RES. ON HUM. RES. ETHICS, Sept. 2011, at 17, 23.
222. See Tutton & Prainsack, supra note 42, at 1082–83.
223. Fullerton et al., supra note 128, at 3.
224. Bartha Maria Knoppers & Ruth Chadwick, Human Genetic Research:
Emerging Trends in Ethics, 6 NATURE REVS. GENETICS 75, 79 (2005).
225. See Terry & Terry, supra note 1, at 1–2.
226. Heather A. Piwowar et al., Towards a Data Sharing Culture:
Recommendations for Leadership from Academic Health Centers, 5 PLOS
MED. 1315, 1315 (2008).
227. See id.
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exceed the risk. The real risk in not creating a dynamic, participant-centric system is too great—translation science and those
awaiting diagnostics and treatments cannot afford that loss.

